HALO News and Press, Halozyme Therapeutics Inc. From 02/23/21

Halozyme Therapeutics (HALO) announces that it intends to offer $500M aggregate principal amount of convertible senior notes due 2027.The company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75M aggregate principal amount of convertible note...

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 PR Newswire SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in convertin...

Halozyme Therapeutics (HALO): Q4 GAAP EPS of $0.50 misses by $0.05.Revenue of $121.7M (+126.8% Y/Y) beats by $0.95M.2021 Guidance: Revenues: $375-395M representing 40% to 48% growth Y/Y; EPS of $1.40 to $1.55 representing 54%-70% growth Y/Y and Operating Income of $215-$235M, representin...

Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results - Reports Fourth Quarter 2020 Revenue of $121.7 million and Earnings Per Share of $0.50 - - Reports Full Year 2020 Revenue of $267.6 million and Earnings Per Share of $0.91 - - Successful Launch of D...

Halozyme has an excellent royalty business that will terminate in 2027. If they plan to acquire another platform, I will feel a lot more bullish. However, their revenues are constantly on the rise. For further details see: Halozyme: Nice Pivot To A Royalty Business

Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call PR Newswire SAN DIEGO , Feb. 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quar...

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis - DARZALEX FASPRO® Utilizing ENHANZE® Represents First and Only Approved Treatment...

Halozyme Therapeutics ([[HALO]] -5.7%) expects its FY21 revenue to range between $375-$395M (+40% to +45% Y/Y), shy of market consensus of $401.22M.The company expects a doubling in revenue from royalties, a significant increase in product sales related to API; however, this guidance exc...

Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected to Double versus Expected 2020 Royalties - - 2021 EP...

Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive offic...